Aprea Therapeutics (APRE) Price & Analysis

Compare

474 Followers

APRE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.41 - $5.01

Previous CloseN/A

Volume2.88K

Average Volume (3M)54.45K

Market Cap

$9.20M

Enterprise Value-$5.52M

Total Cash (Recent Filing)$16.53M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.83

Next Earnings

Nov 06, 2025

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding5,825,261

10 Day Avg. Volume34,309

30 Day Avg. Volume54,454

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.60

Enterprise Value/Revenue-8.14

Enterprise Value/Gross Profit-6.74

Enterprise Value/Ebitda0.37

Forecast

1Y Price Target

$10.00

Price Target Upside525.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentAprea's WEE1i and ATRi candidates have continued to make progress in early stage studies and management continues to execute on its development strategy.

Drug EfficacyThe strategy of continuous dosing has already demonstrated enhanced safety/tolerability profiles as well as early signals of efficacy.

Financial StabilityThe company has a strong management team, good assets/programs and cash runway into 2Q26.

Bears Say

Market ConditionsAPRE shares have pulled back significantly mainly from challenging macro market factors, particularly for microcap biotech.

Market HeadwindsAprea, like many small biotechs, has been pressured by broad market headwinds and a lack of significant catalysts.

Aprea Therapeutics News

Aprea Therapeutics reports Q2 EPS (53c) vs. (58c) last year

Reports Q2 revenue $118,111 vs. $561,574 last year. “We are pleased with our progress in 2025, as emerging...

17d ago

APRE

Aprea Therapeutics sees cash runway into 2Q26

As of June 30, 2025, the Company reported cash and cash equivalents of $16.5 million compared to $22.8...

17d ago

APRE

Positive Outlook for Aprea Therapeutics: Promising Progress in WEE1i and ATRi Candidates Amidst Challenges

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Aprea Therapeutics. The associated price target...

16d ago

APRE

Aprea Therapeutics Reports Promising Q2 2025 Results

Aprea Therapeutics, Inc. ( ($APRE) ) has released its Q2 earnings. Here is a breakdown of the information...

17d ago

APRE

Aprea Therapeutics Reports Q2 2025 Financial Results

Aprea Therapeutics ( ($APRE) ) has issued an announcement. On August 12, 2025, Aprea Therapeutics reported its financial...

17d ago

APRE

Aprea Therapeutics announces new preclinical data, update on APR-1051

Aprea Therapeutics (APRE) announced new preclinical data and a clinical update on APR-1051, the Company’s next-generation oral WEE1...

2M ago

APRE

Aprea Therapeutics Confirms Directors and Accounting Firm

Aprea Therapeutics ( ($APRE) ) has provided an update. At the 2025 annual meeting held on June 5,...

3M ago

APRE

Buy Rating for Aprea Therapeutics: Strong Clinical Progress and Financial Stability

Maxim Group analyst Jason McCarthy maintained a Buy rating on Aprea Therapeutics (APRE – Research Report) on May...

3M ago

APRE

Aprea Therapeutics Reports Q1 2025 Progress and Financials

Aprea Therapeutics, Inc. ( ($APRE) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

APRE

Aprea Therapeutics Reports Promising Q1 2025 Results

Aprea Therapeutics ( ($APRE) ) has issued an update. On May 14, 2025, Aprea Therapeutics announced its financial...

4M ago

APRE

Aprea Therapeutics reports Q1 EPS (66c) vs. (67c) last year

Reports Q1 revenue $162,463 vs. $380,569. “2025 is off to a strong start with significant clinical progress across...

4M ago

APRE

Aprea Therapeutics sees cash runway into 2Q26

As of March 31, 2025, the Company reported cash and cash equivalents of $19.3 million compared to $22.8...

4M ago

APRE

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

APRE

BCDA

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5M ago

CDT

HUT

APRE FAQ

What was Aprea Therapeutics Inc’s price range in the past 12 months?

Aprea Therapeutics Inc lowest stock price was $1.41 and its highest was $5.01 in the past 12 months.

What is Aprea Therapeutics Inc’s market cap?

Aprea Therapeutics Inc’s market cap is $9.20M.

When is Aprea Therapeutics Inc’s upcoming earnings report date?

Aprea Therapeutics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Aprea Therapeutics Inc’s earnings last quarter?

Aprea Therapeutics Inc released its earnings results on Aug 12, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.181.

Is Aprea Therapeutics Inc overvalued?

According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aprea Therapeutics Inc pay dividends?

Aprea Therapeutics Inc does not currently pay dividends.

What is Aprea Therapeutics Inc’s EPS estimate?

Aprea Therapeutics Inc’s EPS estimate is -0.34.

How many shares outstanding does Aprea Therapeutics Inc have?

Aprea Therapeutics Inc has 5,825,261 shares outstanding.

What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?

Aprea Therapeutics Inc reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went up 0.592%.

Which hedge fund is a major shareholder of Aprea Therapeutics Inc?

Currently, no hedge funds are holding shares in APRE

Company Description

Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics (APRE) Earnings & Revenues

Historic Earnings Reports

APRE Stock 12 Month Forecast

Average Price Target

$10.00

▲(525.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.3015384615384615,2.943076923076923,3.5846153846153843,4.226153846153846,4.867692307692307,5.509230769230769,6.150769230769231,6.792307692307692,7.4338461538461535,8.075384615384614,8.716923076923075,9.358461538461539,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.3015384615384615,2.943076923076923,3.5846153846153843,4.226153846153846,4.867692307692307,5.509230769230769,6.150769230769231,6.792307692307692,7.4338461538461535,8.075384615384614,8.716923076923075,9.358461538461539,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.66,2.3015384615384615,2.943076923076923,3.5846153846153843,4.226153846153846,4.867692307692307,5.509230769230769,6.150769230769231,6.792307692307692,7.4338461538461535,8.075384615384614,8.716923076923075,9.358461538461539,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >